Table 2 Overall survival stratified by haematologic response- ITT, 1-month, 3-month and 6-month landmark cohorts.
From: Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
CR | VGPR | PR | NR | p value | |
n | n | n | n | ||
Median OS, months (95% CI, months) | Median OS, months (95% CI, months) | Median OS, months (95% CI, months) | Median OS, months (95% CI, months) | ||
ITT cohort Evaluable patients = 1194 | n = 137 | n = 270 | n = 252 | n = 413 | <0.005 |
Median not reached | Median not reached | Median OS 61 months (95% CI 43.42–78.57 months) | Median OS 22 months (95% CI 14.54–29.45 months) | ||
1-month landmark cohort Evaluable patients = 1011 | n = 137 | n = 270 | n = 252 | n = 352 | <0.005 |
Median not reached | Median not reached | Median OS 60 months (95% CI 42.42–77.57 months) | Median OS 32 months (95% CI 25.36-38.63 months | ||
3-month landmark cohort Evaluable patients = 985 | n = 290 | n = 303 | n = 213 | n = 179 | <0.005 |
Median not reached | Median not reached | Median OS 47 months (95% CI 27.51–66.48 months) | Median OS 23 months (95% CI 15.93–30.06 months | ||
6-month landmark cohort Evaluable patients = 915 | n = 294 | n = 323 | n = 194 | n = 104 | <0.005 |
Median not reached | Median not reached | Median OS 42 months (95% CI 27.91–56.09 months) | Median OS 22 months (95% CI 16.39–27.60 months) |
